Concordance of Early and Late End Points for Community-acquired Bacterial Pneumonia Trials.

Bart, Stephen M; Nambiar, Sumathi; Gopinath, Ramya; Rubin, Daniel; Farley, John J

Bart, Stephen M; Nambiar, Sumathi; Gopinath, Ramya; Rubin, Daniel; Farley, John J.

Afiliação

Bart SM; Office of Infectious Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Nambiar S; Office of Infectious Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Gopinath R; Office of Infectious Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Rubin D; Division of Biometrics IV, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Farley JJ; Office of Infectious Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Clin Infect Dis ; 73(9): e2607-e2612, 2021 11 02.

Article em En | MEDLINE | ID: mdl-32584969

Assuntos

Anti-Infecciosos; Infecções Comunitárias Adquiridas; Pneumonia Bacteriana; Antibacterianos/uso terapêutico; Bactérias; Infecções Comunitárias Adquiridas/tratamento farmacológico; Humanos; Pneumonia Bacteriana/tratamento farmacológico

Palavras-chave

antibacterial drug development; community-acquired bacterial pneumonia; early clinical response; end point

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Comunitárias Adquiridas / Pneumonia Bacteriana / Anti-Infecciosos Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google